Enovis (ENOV) Expected to Announce Earnings on Thursday

Enovis (NYSE:ENOV) is projected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Enovis to post earnings of $0.81 per share and revenue of $584.30 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Enovis Trading Down 1.5%

Enovis stock opened at $22.39 on Tuesday. Enovis has a one year low of $21.00 and a one year high of $43.76. The company’s fifty day moving average price is $24.50 and its two-hundred day moving average price is $28.31. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.22 and a quick ratio of 1.16. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -0.95 and a beta of 1.52.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ENOV. BTIG Research started coverage on Enovis in a report on Tuesday, January 6th. They set a “buy” rating and a $41.00 price objective on the stock. UBS Group reiterated a “buy” rating and set a $50.00 price target on shares of Enovis in a report on Monday, January 5th. Evercore restated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Wells Fargo & Company upped their price objective on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, Canaccord Genuity Group dropped their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $46.71.

Insider Transactions at Enovis

In related news, EVP Daniel A. Pryor sold 999 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total transaction of $27,172.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ENOV. Arax Advisory Partners acquired a new position in shares of Enovis during the fourth quarter valued at about $29,000. EverSource Wealth Advisors LLC increased its stake in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the period. Danske Bank A S acquired a new position in Enovis in the 3rd quarter valued at approximately $64,000. iSAM Funds UK Ltd acquired a new position in Enovis in the 3rd quarter valued at approximately $80,000. Finally, Brown Brothers Harriman & Co. bought a new stake in shares of Enovis in the 3rd quarter worth approximately $90,000. Institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.